Updated Phase 2 CAPTIVATE study results demonstrate sustained ...

Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first ...

At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM, ...

Updated phase 2 CAPTIVATE study results demonstrate sustained ...

At 5 years, 67% of patients were progression-free, with overall survival at 96% for all treated patients.

5.5-year results from the phase 2 ICLL-07 FILO trial - PubMed Central

In CLL, fixed-duration immunochemotherapy (15 months) produced deep and sustained PB MRD responses and high survival rates. No differences were apparent in ...

Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic ...

Results from the CAPTIVATE study demonstrated that first-line ibrutinib plus venetoclax provides deep, durable responses and sustained progression-free ...

Dr Ryan Jacobs Highlights Sustained Success in Patients With CLL ...

Ryan Jacobs, MD, of Atrium Health Levine Cancer Institute, explains that the phase 2 CAPTIVATE study's fixed-duration treatment cohort shows ...

5-Year CAPTIVATE Results Show Promise in CLL/SLL With Ibrutinib ...

Targeted Oncology: Please provide some background information on the CAPTIVATE study. Ghia: The CAPTIVATE study is phase 2, international study ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results ...

A Study of the Combination of Ibrutinib Plus Venetoclax Versus ...

GlobeNewswire 2024 - Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical beneﬁt of ﬁxed-duration IMBRUVICA (ibrutinib) plus venetoclax ...

Phase II CAPTIVATE Study - Slideset Download - Hematology 2019

Initial results from the phase II CAPTIVATE trial demonstrated that ibrutinib plus venetoclax yielded high rates of undetectable MRD in patients with ...

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic ...

CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first- ...

Five-year follow-up of the CAPTIVATE trial - YouTube

Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, shares the results from a five-year follow-up of the Phase II CAPTIVATE ...

Promising Data in CLL With Ibrutinib/Venetoclax Doublet

Findings from the phase 2 CAPTIVATE study demonstrate that the doublet of ibrutinib and venetoclax may be an attractive line of therapy for ...

Fixed-Duration CAPTIVATE Regimen Is Effective in CLL Regardless ...

... findings of a post hoc analysis of the phase 2 CAPTIVATE study (NCT02910583). The results, published in Clinical Cancer Research, examined ...

Immune restoration with ibrutinib plus venetoclax in first-line chronic ...

CAPTIVATE (NCT02910583) is an international, multicenter phase 2 study evaluating first-line ibrutinib plus venetoclax in patients with ...

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic ...

P2 | N=323 | CAPTIVATE (NCT02910583) | Sponsor: Pharmacyclics LLC. | "Latest findings from the multicentre Phase 2 CAPTIVATE study showed that at a median ...

Ibrutinib and venetoclax continue to provide benefits for patients with ...

Dr Paolo Ghia talks to ecancer about the phase 2 CAPTIVATE study. It demonstrated that first-line treatment with ibrutinib and venetoclax in ...

Fixed-duration Ibrutinib Plus Venetoclax May Benefit Patients with ...

“Previously reported results from the CAPTIVATE study demonstrated deep and durable responses with sustained PFS after fixed-duration ...

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

... results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 2021;39:3853-3865. Crossref · PubMed.

Immune restoration with ibrutinib plus venetoclax in first-line chronic ...

CAPTIVATE (NCT02910583 ) is an international, multicenter phase 2 study evaluating first-line ibrutinib plus venetoclax in patients with ...